Claims

- 1. Use of substances that bind to the components of the cytoskeleton, especially to EF-Tu, for cell digestion.
 - 2. Use according to claim 1 for cell digestion of bacteria cells.
- 3. Use according to claim 1 or 2, characterized in that the substances bind to the EF-Tu in the area of the domain 2 (amino acids 205 to 298) and/or of the domain 3 (amino acids 299 to 349).
- 4. Use according to one of the preceding claims, wherein the substances bind to the EF-Tu in the area of the amino acids 218 to 224 of the domain 2 and/or in the area of amino acids 317 to 328 and/or 343 to 354 of the domain 3.
- 5. Use according to one of the preceding claims, wherein the substances contain partial segments of the amino acid sequences from the domains 2 and/or 3 with a length of at least four amino acids.
- 6. Use according to claim 5, wherein the partial segments have a length from 5 to 15 amino acids, especially from 6 to 12 amino acids.
- 7. Use according to one of claims 1 to 5, wherein the substances contain the domain 3 of EF-Tu and no other domain of EF-Tu.
- 8. Use according to one of the preceding claims, wherein the substances are chosen from linear or cyclic peptide compounds or peptide mimetic agents.
- 9. Process for digestion of cells, wherein components of the cytoskeleton are destabilized in the cells.

- 10. Process according to claim 9, wherein substances that bind to the components of the cytoskeleton are used for destabilization.
 - 11. Process according to claim 9 or 10, wherein substances that bind to EF-Tu are used.
- 12. Process according to one of claims 9 to 11, wherein substances are used that bind to the EF-Tu in the area of the domain 2 (amino acids 205 to 298) and/or domain 3 (amino acids 299 to 394), especially in the area of amino acids 218 to 224 of the domain 2 and/or in the area of amino acids 317 to 328 and/or 343 to 354 of the domain 3.
- 13. Process according to one of claims 12 or 13, wherein substances are used that contain partial segments of the amino acid sequences from the domains 2 and/or 3 with a length of at least 4 amino acids, especially of at least 5 amino acids.
- 14. Process according to one of claims 10 to 13, wherein nucleic acids are introduced into the cells that code for the substances that destabilize the cytoskeleton.
- 15. Process for producing a compound, wherein cells are used into which a sequence has been introduced, coding for a compound that destabilizes components of the cytoskeleton of the cells, the cells are cultivated and in this way the desired intracellular compound is obtained.
- 16. Process according to claim 15, wherein the desired compound is intracellularly produced by cultivation of cells and, in a second step, lysis of the cells is caused by induction of expression of the compound that destabilizes the cytoskeleton.
- 17. Process according to one of claims 16 [sic], wherein the desired compound is formed by heterologous expression.
- 18. Process according to one of claims 16 [sic], wherein the desired compound is formed by homologous expression.

- 19. Process according to one of claims 16 to 20, wherein induction takes place by quorum sensing.
- 20. Process according to one of claims 16 to 20, wherein the sequence that codes for a compound that destabilizes the cytoskeleton of the cells in a construct is introduced into the cells, the construct containing additional regions that allow an induction of the synthesis of the compound.
- 21. Construct, comprising a sequence that codes for a compound that destabilizes components of the cytoskeleton of cells.
- 22. Construct according to claim 21, furthermore comprising a gene segment that allows the induction of synthesis of the compound that destabilizes the cytoskeleton.